Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT · NASDAQ Global Market
+$0.06 today
Vol 8.17M · Avg 3.15M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:RCKT · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$209.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.87, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $11.0M | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$11.0M | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $142.0M -17.1% | $171.2M -8.1% | $186.3M +12.5% | $165.6M +32.0% | $125.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $86.5M -15.2% | $102.0M +39.1% | $73.3M +24.7% | $58.8M +40.7% | $41.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $217.5M -20.4% | $273.2M +5.2% | $259.7M +15.7% | $224.3M +34.1% | $167.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $11.0M +17.6% | $9.4M +32.1% | $7.1M +13.3% | $6.3M +16.6% | $5.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$210.2M +15.1% | -$247.5M -4.6% | -$236.6M -10.7% | -$213.7M -35.4% | -$157.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$228.5M +16.4% | -$273.2M -5.2% | -$259.7M -15.7% | -$224.3M -34.1% | -$167.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $10.6M -41.7% | $18.2M +14.3% | $15.9M +309.8% | $3.9M +26.8% | $3.1M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.9M +0.3% | $1.9M +0.6% | $1.9M -1.8% | $1.9M -67.6% | $5.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $5.4M -62.7% | $14.5M +2.8% | $14.1M +467.1% | $2.5M +236.2% | -$1.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$223.1M +13.8% | -$258.7M -5.4% | -$245.6M -10.7% | -$221.9M -31.2% | -$169.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$223.1M +13.8% | -$258.7M -5.4% | -$245.6M -10.7% | -$221.9M -31.2% | -$169.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +26.4% | -$3 +6.5% | -$3 +10.4% | -$3 -21.6% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +26.4% | -$3 +6.5% | -$3 +10.4% | -$3 -21.6% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $111.1M +17.2% | $94.8M +12.9% | $84.0M +23.3% | $68.1M +7.8% | $63.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $111.1M +17.2% | $94.8M +12.9% | $84.0M +23.3% | $68.1M +7.8% | $63.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$847.81M
Design Therapeutics, Inc.
NASDAQ:DSGN
$756.04M
Solid Biosciences Inc.
NASDAQ:SLDB
$603.80M
Annexon, Inc.
NASDAQ:ANNX
$586.12M
Autolus Therapeutics plc
NASDAQ:AUTL
$409.86M
Aura Biosciences, Inc.
NASDAQ:AURA
$398.68M
DBV Technologies S.A.
NASDAQ:DBVT
$377.25M
I-Mab
IMAB
$235.66M
Quantum-Si incorporated
NASDAQ:QSI
$193.45M
Galectin Therapeutics Inc.
NASDAQ:GALT
$183.74M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RCKT generate?
Rocket Pharmaceuticals, Inc. (RCKT) reported $0.00 of revenue in fiscal 2025.
Is RCKT profitable?
Rocket Pharmaceuticals, Inc. (RCKT) reported -$223,123,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.